Ontology highlight
ABSTRACT: Clinical trial registration number
JapicCTI-132072.
SUBMITTER: Hida T
PROVIDER: S-EPMC5448646 | biostudies-literature | 2017 May
REPOSITORIES: biostudies-literature
Hida Toyoaki T Nishio Makoto M Nogami Naoyuki N Ohe Yuichiro Y Nokihara Hiroshi H Sakai Hiroshi H Satouchi Miyako M Nakagawa Kazuhiko K Takenoyama Mitsuhiro M Isobe Hiroshi H Fujita Shiro S Tanaka Hiroshi H Minato Koichi K Takahashi Toshiaki T Maemondo Makoto M Takeda Koji K Saka Hideo H Goto Koichi K Atagi Shinji S Hirashima Tomonori T Sumiyoshi Naoki N Tamura Tomohide T
Cancer science 20170426 5
Limited treatment options are available for stage IIIB/IV non-small cell lung cancer (NSCLC). Nivolumab, a programmed cell death-1 immune checkpoint inhibitor antibody, has been shown to be effective for the treatment of NSCLC. The present study investigated the effectiveness and safety of nivolumab in Japanese patients with advanced or recurrent squamous NSCLC that progressed after platinum-containing chemotherapy. In this multicenter phase II study, patients were treated with nivolumab (3 mg/k ...[more]